|
Isabelle Arnulf, MD
(Hopital Pitie-Salpetriere)
|
Dr. Arnulf has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for ONO Pharma. Dr. Arnulf has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for ROCHE pharma. Dr. Arnulf has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for IDORSIA Pharma. Dr. Arnulf has received personal compensation in the range of $0-$499 for serving on a Speakers Bureau for UCB Pharma. The institution of Dr. Arnulf has received research support from BIOPROJET pharma. The institution of Dr. Arnulf has received research support from VITALAIRE. The institution of Dr. Arnulf has received research support from French SLEEP Socity (SFRMS). The institution of Dr. Arnulf has received research support from Paris Brain Insitute. Dr. Arnulf has a non-compensated relationship as a scientific advisory with Jazz Pharma that is relevant to AAN interests or activities. Dr. Arnulf has a non-compensated relationship as a scientific advisory with Theranexus that is relevant to AAN interests or activities. |